Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 321,500 |
|
|||||
| News | - | ||||||
| Day High | 0.47 | Low High |
|||||
| Day Low | 0.4579 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| BioVie Inc | BIVI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0095 | -2.06% | 0.4525 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.47 | 0.4579 | 0.47 | 0.4488 | 0.462 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,720 | 321,500 | US$ 0.4631152 | US$ 148,892 | - | 0.405 - 6.31 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:32:23 | formt | 10,000 | US$ 0.4525 | USD |
BioVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.74M | 39.87M | - | 0 | -50.26M | -1.26 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioVie News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/17/2024 | 16:05 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 6/12/2024 | 07:24 | GlobeNewswire Inc. | Join BioVie’s Exclusive Live Investor Webinar and Q&A.. |
| 6/07/2024 | 16:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 5/14/2024 | 16:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 3/14/2024 | 04:45 | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of BioVie Inc... |
| 3/11/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/11/2024 | 04:45 | PR Newswire (US) | BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie.. |
| 3/07/2024 | 04:45 | PR Newswire (US) | Contact The Gross Law Firm by March 19, 2024 Deadline to.. |
| 3/06/2024 | 16:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/04/2024 | 16:28 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
| 3/04/2024 | 16:28 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 3/04/2024 | 06:50 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.46 | 0.4998 | 0.44 | 0.4797414 | 446,833 | -0.0075 | -1.63% |
| 1 Month | 0.4803 | 0.4998 | 0.405 | 0.4668017 | 518,289 | -0.0278 | -5.79% |
| 3 Months | 0.5669 | 0.5698 | 0.405 | 0.4894922 | 626,060 | -0.1144 | -20.18% |
| 6 Months | 1.42 | 3.31 | 0.405 | 1.31 | 1,518,649 | -0.9675 | -68.13% |
| 1 Year | 5.41 | 6.31 | 0.405 | 1.81 | 1,004,489 | -4.96 | -91.64% |
| 3 Years | 17.24 | 17.9006 | 0.405 | 3.55 | 525,446 | -16.79 | -97.38% |
| 5 Years | 10.50 | 46.0977 | 0.405 | 4.16 | 436,116 | -10.05 | -95.69% |
BioVie Description
| BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
